

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/660,929	09/12/2003	Kazuo Takeda	82478-0700	7311
21611 7590 05/08/2007 SNELL & WILMER LLP (OC) 600 ANTON BOULEVARD			EXAMINER	
			VO, TUYET THI	
SUITE 1400 COSTA MESA, CA 92626			ART UNIT .	PAPER NUMBER
	•		2821	
			MAIL DATE	DELIVERY MODE
			05/08/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

DATE MAILED:



Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
10660929	9/12/03	TAKEDA ET AL.	AL. 82478-0700 EXAMINER	
SNELL & WILMER LLP (OC) 600 ANTON BOULEVARD .			Tuyet Vo	
SUITE 1400 COSTA MESA, CA 9	2626	26		PAPER
			2821	20070502

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The Informatin Disclosure Statement filed August 01, 2006 has been initialed and sent to the applicant for recording purpose.

The information disclosure statement was filed September 11, 2006 after the issue fee paid will not be considered, but will be placed in the file. However, the application may be withdrawn from issue in order to file a request for continued examination (RCE) under 37 CFR 1.114 upon the grant of a petition under 37 CFR 1.313(c)(2). Alternatively, the other provisions of 37 CFR 1.313 may apply, e.g., a petition to withdraw the application from issue under the provisions of 37 CFR 1.313(c)(1) may be filed together with an unequivocal statement by the applicant that one or more claims are unpatentable over the information contained in the statement. The information disclosure statement would then be considered upon withdrawal of the application from issue under 37 CFR 1.313(c)(1).

Tuyet Thi Vo Primary examiner